Investor Relations
Mar 16, 2018
OPKO Health Announces Landmark Study Showing 4Kscore® Test is Strong Predictor of Prostate Cancer Mortality Published in European Urology MORE >>
Mar 01, 2018
OPKO Health Reports 2017 Fourth Quarter Business Highlights and Financial Results MORE >>
Feb 26, 2018
OPKO Health to Announce Fourth Quarter and Year End 2017 Financial Results on March 1, 2018 MORE >>
Jan 26, 2018
OPKO Health Announces Leadership Changes at BioReference Laboratories MORE >>
<< Back
Mar 14, 2017

OPKO Health to Participate in the Barclays Global Healthcare Conference

MIAMI, March 14, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announces that senior management will participate at the Barclays Global Healthcare Conference taking place March 14-16, 2017 at Loew's Miami Beach Hotel.  Company management will deliver a corporate overview on Wednesday, March 15, 2017 at 3:20 p.m. ET

The Company's presentation will be webcast live on the OPKO Investor Relations page of the corporate website at To access the live webcast please log onto the OPKO website approximately fifteen minutes before the presentation to register and download any necessary audio software. The audio presentation will be available at this link for a limited time after the live presentation.

About OPKO Health
OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists (phase 2), and TT701, an androgen receptor modulator for androgen deficiency indications (phase 2). Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia (in phase 2a).  We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at


OPKO Health, Inc.
David Malina, 305-575-4137 

Rooney Partners
Terry Rooney, 212-223-0689 
Marion Janic, 212-223-4017 

Anne Marie Fields, 212-838-3777 
Bruce Voss, 310-691-7100 


Primary Logo

Source: OPKO Health Inc.

News Provided by Acquire Media